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Abstract Pregnant women with heart disease often have an
increased risk of maternal cardiovascular and offspring
complications. The magnitude of these risks varies depending
on the type and severity of the underlying disease. Therefore
risk assessment should be performed before pregnancy. This
can be accomplished by taking into account predictors and
risk scores that have been developed in large populations of
pregnant women with heart disease, as well as by consulting
disease-specific pregnancy literature. A system that integrates
all available knowledge about the risk of pregnancy is the
adapted World Health Organisation risk classification. The
safety of pregnancy for women with heart disease can be
enhanced by adequate risk assessment and counselling.
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Introduction
The prevalence of maternal heart disease during pregnancy
is estimated at 0.5–1% and is increasing. While rheumatic
heart disease is most prevalent in developing countries, in
the Western world congenital heart disease (CHD) con-
stitutes 80% of maternal heart disease [1, 2]. Pregnancy
induces haemodynamic changes (increased intravascular
volume and cardiac output, decreased systemic vascular
resistance and hypercoagulable state) which are associated
with increased risk for mother and foetus when maternal
heart disease is present. In the UK, heart disease is now the
most important cause of maternal death, and in the
Netherlands it is the most frequent indirect cause [3]. Many
deaths occurred in women who were previously not known
to have heart disease, and substandard care contributed in
many cases. A high level of suspicion for heart disease may
therefore prevent fatal outcome. Maternal mortality is,
however, just the tip of the iceberg: maternal morbidity
and offspring morbidity and mortality are far more
important numerically. The most prevalent maternal cardio-
vascular complications that occur during pregnancy are
heart failure, arrhythmias, thromboembolic events, and
aortic dissection. In women with a known history of heart
disease, full investigation pre-pregnancy and expert risk
assessment and counselling are extremely important. This
prevents women from embarking on pregnancy when the risk
for their lives is high, it allows for interventions to be carried
outbeforepregnancyifnecessary,andamanagementplancan
be timely established for the many women who can be
expected to go through a relatively safe pregnancy. Our
knowledge concerning pregnancy complications and risk
estimation in women with heart disease has increased over
the years, thus contributing to improved counselling of these
women and better care during their pregnancies. This article
reviews the recent literature on this subject.
Pregnancy complications and prediction of maternal
outcome
Predictors and risk scores
Independent predictors of maternal cardiovascular compli-
cations during pregnancy have been identified in recent and
older studies [1, 4–8]. An overview of these predictors is
presented in Table 1. In addition to previously recognised
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ventricular outflow tract obstruction, cyanosis, arrhythmias,
ventricular dysfunction, pulmonary hypertension and me-
chanical valve prosthesis, several new predictors have come
forward in recent studies. The use of cardiac medication
pre-pregnancy predicted cardiovascular complications in
two studies [7, 8] and is most likely a surrogate marker for
severity of heart disease. Also, in CHD, underlying
corrected or uncorrected cyanotic heart disease was
associated with maternal outcome which probably reflects
greater complexity of the underlying lesion. This is in line
with a large systematic review concerning pregnancy and
CHD [9]. Atrioventricular valvular regurgitation (mitral or
tricuspid regurgitation) emerged as an independent predic-
tor of maternal cardiac complications in a large retrospec-
tive study, despite the beneficial effect of decreasing
vascular resistance during pregnancy. The large population
may have allowed weaker predictors of complications to be
identified. Additionally, some of the patients had complex
underlying heart disease and compromised ventricular
function which possibly added to the complication rate [7].
A potentially useful new predictor of maternal cardiac
events is B-type natriuretic peptide (BNP). Importantly,
BNP (≤100 pg/ml) (mainly obtained during the first
trimester) had a negative predictive value of 100% for
adverse cardiac events [8]. More data concerning NT-
proBNP in pregnant women with heart disease can be
expected in the near future [10]. In 2001, the CARPREG
investigators presented a risk score to estimate maternal
cardiovascular risk of complications in women with acquired
Table 1 Predictors of maternal cardiovascular complications during pregnancy
Predictor Study Population Risk
points
CARPREG
Prior cardiac event (heart failure, transient ischaemic attack, stroke, arrhythmia) CARPREG CHD, AHD 1
NYHA functional class III/IV or cyanosis (SO
2 <90%) CARPREG CHD, AHD 1
Left heart obstruction (mitral valve area <2 cm² or aortic valve area <1.5 cm² or peak
LVOT gradient >30 mmHg (echocardiography)
CARPREG CHD, AHD 1
Reduced systemic ventricular systolic function (EF <40%) CARPREG CHD, AHD 1
ZAHARA
Prior arrhythmia ZAHARA CHD 1.50
NYHA functional class III/IV ZAHARA CHD 0.75
Left heart obstruction (peak LVOT gradient >50 mmHg or aortic valve area <1.0 cm² ZAHARA CHD 2.50
Mechanical valve prosthesis ZAHARA CHD 4.25
Systemic AV valve regurgitation (moderate/severe) ZAHARA CHD 0.75
Pulmonary AV valve regurgitation (moderate/severe) ZAHARA CHD 0.75
Cardiac medication before pregnancy ZAHARA CHD 1.50
Cyanotic heart disease (corrected and uncorrected) ZAHARA CHD 1.00
OTHER STUDIES
Prior cardiac event (heart failure, transient ischaemic attack, stroke, arrhythmia) Tanous CHD, AHD
NYHA functional class III/IV Song CHD
Kovavisarach CHD, AHD
Cardiac medication before pregnancy Tanous CHD, AHD
Anticoagulation therapy Tanous CHD, AHD
Pulmonary arterial hypertension Song CHD
Maximum BNP >100 pg/ml Tanous CHD, AHD
Smoking history Khairy CHD
Reduced subpulmonary ventricular function and/or severe pulmonary regurgitation Khairy CHD
Right ventricular dilataton Song CHD
CARPREG risk score: For each CARPREG predictor that is present, 1 point is assigned to the pregnancy. The risk score is the total number of
points. The risk of maternal cardiovascular complications is 5% with 0 points, 27% with 1 point and 75% with ≥1 point
ZAHARA risk score: For each ZAHARA predictor that is present, a predictor-specific number of points is assigned to the pregnancy, according to
the table. The risk of maternal cardiovascular complications is 2.9% with <0.5 points, 7.5% with 0.5–1.5 points, 17.5% with 1.51–2.50 points,
43.1% with 2.51–3.5 points and 70% with >3.5 points. AHD=acquired heart disease; AV=atrioventricular; BNP=B-type natriuretic peptide; CHD
=congenital heart disease, EF=ejection fraction, LVOT=left ventricular outflow tract, NYHA=New York Heart Association
478 Neth Heart J (2011) 19:477–481or congenital heart disease [1]( T a b l e1). In recent years,
several studies have validated this risk score [2, 7, 11]. The
CARPREG risk score does identify pregnancies with higher
risk, but overestimates the actual risk according to most
studies (Table 2). The ZAHARA investigators recently
published a risk score developed in a large population with
CHD [7] (Table 1). This risk score was prospectively
validated in the ZAHARA II study and performed better in
a population with CHD than the CARPREG risk score [12].
It is important to realise the limitations of predictors and
risk scores. They are highly population-dependant: the
magnitude as well as the composition of the population
determine which predictors will emerge in a certain study.
Given the heterogeneity of the population of pregnant women
with heart disease, especially in Western countries with a high
percentage of CHD, these limitations are of practical
importance. To illustrate this, the CARPREG and ZAHARA
risk scores failed to identify pulmonary arterial hypertension
and dilated aorta as predictors of pregnancy outcome: low
prevalence of these predictors is the likely explanation.
Therefore, to estimate the risk of pregnancy, these
predictors and risk scores are just one of the tools that
must be used. Additionally, disease-specific information
should always be taken into account.
Disease-specific information
Congenital heart disease
Most women with congenital heart disease tolerate preg-
nancy well. The risk of cardiovascular complications
increases with increasing complexity of the underlying
disease. This is illustrated in a large review that included
2491 pregnancies [9]. This review provides the incidence of
cardiovascular complications (heart failure, arrhythmias and
cardiovascular events separately) for 14 congenital heart
disease diagnoses and can be used as a quick reference.
While cardiac complications are rare (<5%) in women with
atrial or ventricular septal defect and pulmonary stenosis,
they occur frequently (>15%) in women with transposition
of the great arteries, Eisenmenger syndrome, Fontan
circulation and uncorrected or palliated cyanotic heart
disease. In women with an atrioventricular septal defect, atrial
correction of transposition, tetralogy of Fallot and Fontan
circulation,arrhythmiasarethemostfrequentcomplication.In
aortic stenosis, pulmonary atresia with ventricular septal
defect and uncorrected or palliated cyanotic heart disease,
heart failure is the main complication [9].
Valvular heart disease
Mitral stenosis is the most frequent cardiac diagnosis in
pregnant women with rheumatic heart disease and is not
well tolerated during pregnancy [1, 5, 13]. Even moderate
mitral stenosis predicts worse outcome and should be
treated interventionally before pregnancy [1, 13]. Aortic
stenosis in pregnant women is mostly congenital in origin
and, according to recent studies, is better tolerated than
previously thought, even when it is severe [14]. Symptom-
atic aortic stenosis should, however, be corrected before
pregnancy. The choice of valve prosthesis should then be
carefully considered. Bioprostheses have a low complica-
tion rate during pregnancy but valve degeneration, ulti-
mately leading to reoperation, is a problem in women at
young age. The Ross operation may be an alternative in
experienced hands. Data on pregnancy after the Ross
operation are scarce, but promising [15]. Mechanical
prostheses carry a high complication rate. The most
important complication is valve thrombosis. In the Dutch
ZAHARA I study, even though the prevalence of pregnan-
cies with a mechanical valve was low, the presence of a
mechanical valve was still the strongest predictor of
maternal complications [7] (Table 1). The necessity for
anticoagulation therapy raises the dilemma to continue
vitamin K antagonists throughout the first trimester with a
relatively low risk of valve thrombosis (±2%) but with the
risk of embryopathy (on average 6%), or to eliminate the
risk of embryopathy by substituting the oral anticoagulant
with unfractionated or low-molecular-weight heparin and
accept a higher risk of valve thrombosis. Expert opinion
diverges on this subject. An open and full discussion with
the mother-to-be should already take place before pregnan-
cy. Such a discussion should make clear that the foetus is
not only threatened by embryopathy, but also by valve
Table 2 External validation of the CARPREG risk score for cardiovascular complications in pregnancy in women with heart disease
CARPREG N=599 Khairy N=90 Curtis N=177 ZAHARA N=1302 Tanous N=66 Jastrow N=312
Risk score–% complications % complications
0–5% 12 5 6 2 1.4
1–27% 30 18 16 30 19
≥1–75% 100 57 22 50 –
LVOT left ventricular outflow tract, NYHA New York Heart Association
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foetus or which may lead to foetal neurological damage
when acute valve surgery is necessary during pregnancy.
The risk of foetal complications is low when the use of oral
anticoagulant therapy is avoided in the first trimester.
Therefore the new European Society of Cardiology (ESC)
guidelines [13] recommend vitamin K antagonists as the
anticoagulation of choice in the 2nd and 3rd trimester.
Moreover, since the occurrence of embryopathy appears to
be dose-dependant, it is recommended to consider contin-
uation of oral anticoagulants when the dose requirement is
low (i.e. warfarin <5 mg daily which is equivalent to
acenocoumarol <2 mg daily). With higher dose require-
ments, unfractionated heparin or low-molecular-weight
heparin can be used from week 6–12. Strict control of the
anticoagulation effect is necessary. For unfractionated
heparin, APTT >2 times control is advised. When low-
molecular-weight heparin is used, anti-factor Xa levels need
to be monitored. However, optimal peak anti-factor Xa
levels are not known; usually the recommendation is 0.8–
1.2 U/l 4 h post-dose. Since rise of glomerular filtration rate
during pregnancy can cause pre-dose levels to be low even
when peak anti-factor Xa levels are adequate, there is an
argument for additional monitoring of pre-dose levels, but
data on the consequences of pre-dose level monitoring in
pregnant women with mechanical valves are lacking.
Aortic disease
Women with aortic dilatation based on underlying Marfan
syndrome have a high risk of dissection during pregnancy
whenthe aorticdiameteris>45mm. Pre-pregnancysurgeryis
then recommended. When aortic diameter is <40 mm preg-
nancy is relatively safe. In women with bicuspid aortic valve
and aortic dilatation, a pre-pregnancy diameter of >50 mm is
considered a contraindication for pregnancy [13].
Cardiomyopathy
Disease-specific information on cardiomyopathies is sum-
marised in a recent review and in the ESC guidelines [13,
16]. Hypertrophic cardiomyopathy is often well-tolerated.
The occurrence of complications is mainly dependant on
pre-pregnancy NYHA class and on left ventricular outflow
obstruction. In dilated cardiomyopathy the risk of pregnan-
cy is dependant on pre-pregnancy NYHA class and on left
ventricular function.
Risk for the offspring
Not only maternal cardiac events, but also offspring events
occur more often in women with heart disease. Premature
delivery, too low birth weight for the gestational age,
offspring mortality and congenital heart disease occur more
often compared with healthy women. Maternal and off-
spring events appeared to be highly related in the
ZAHARA I study (r=0.85) [7]. Comparable to maternal
cardiovascular events, offspring events appear to be
dependant on disease complexity [9]. Predictors for
offspring events that have been identified in the CARPREG
and ZAHARA I studies are multiple pregnancy, smoking
during pregnancy, NYHA class III/IV, left heart obstruction,
heparin/warfarin during pregnancy, other cardiac medica-
tion during pregnancy, cyanosis and a mechanical valve
prosthesis [1, 7].
Risk estimation: an integrated approach
A system that integrates all available knowledge was
proposed by an English group of experts. They adapted
the World Health Organisation (WHO) classification for
use of contraceptive methods to classify the maternal
risk of pregnancy associated with specific cardiovascular
conditions [17]. Pregnancies are classified into four
categories (WHO class I-IV): low, medium and high risk
of pregnancy as well as contraindication for pregnancy.
This classification combines the knowledge of disease-
specific literature with the predictors of pregnancy
outcome known at that time. The authors provide a
collection of tables that apply the classification in a
practical way. Examples of conditions with low risk
(WHO I) are mild pulmonary stenosis or surgically
corrected ventricular or atrial septal defect. A contraindi-
cation to become pregnant (WHO IV) is present in women
with pulmonary arterial hypertension, severe systemic
ventricular dysfunction, severe mitral stenosis, severe
symptomatic aortic stenosis, Marfan syndrome with aortic
dilatation >45 mm, and peripartum cardiomyopathy with
residual ventricular dysfunction. Women with a mechan-
ical prosthetic valve, a systemic right ventricle, unrepaired
cyanotic disease or Fontan circulation have a high risk
(WHO III). For most other diagnoses, it depends on the
severity of the valvular or ventricular dysfunction and the
presence of one or more diagnoses whether they are
assigned to WHO class II or to class III. Therefore, in
some cases expert experience and knowledge will influ-
ence the classification.
The adapted WHO classification was the most
accurate system for risk evaluation in a prospective
evaluation of several risk estimation models [12]. It is
advocated in the new ESC guidelines for the management
of cardiovascular diseases during pregnancy as the risk
estimation system of choice [13]. Management advice is
assigned to these risk classes. While for women with low or
moderaterisk(WHOclassIorII)cardiologyfollow-upcanbe
limited to once per trimester or even less, women in WHO
480 Neth Heart J (2011) 19:477–481class III and IV have a high or very high risk. These women
benefit from frequent control (monthly or bimonthly) in a
specialised centre.
Counselling of women with heart disease
The counselling of cardiac patients about the risk of
pregnancy should commence as soon as they become
sexually active. Especially girls who have a high risk
should be notified about the necessity to plan future
pregnancies carefully. Adequate advice concerning contra-
ception should be offered. At this young age it will not be
necessary to give detailed information about pregnancy, but
the paediatric cardiologist must repeatedly discuss the need
to use a reliable contraceptive. After transition to adult
cardiology the young woman should again be reminded to
discuss her pregnancy wish with her cardiologist before
actually getting pregnant. When a woman wants to get
pregnant, clinical assessment including echocardiography,
exercise testing and sometimes 24-hour ECG and MRI
is indicated. Based on these data, risk assessment can
be performed. When it is decided that the woman can
carry on and attempt to get pregnant, each medicine that
she is using should be reviewed: is it necessary to
continue this medication throughout pregnancy, or can it
be safely discontinued, or should it be replaced by a
safer alternative? A plan for cardiology and obstetric
supervision during pregnancy must be made: when and
where should the woman be seen for the first time by
these specialists? When the heart disease has a genetic
basis referral to a geneticist is often indicated. Finally,
normal pregnancy care, such as the advice to start folic
acid, should not be forgotten.
In conclusion, many women with heart disease can go
through pregnancy with few or no complications. The
safety of pregnancy for women with heart disease can be
enhanced by adequate risk assessment and counselling.
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